| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-12-26 | Vivus (USA - CA) | chief executive officer | nomination | Resignation | ||
| 2017-12-26 | HTG Molecular Diagnostics (USA - AZ) Merck KGaA (Germany) | companion diagnostic | development | Cancer - Oncology | Collaboration agreement | |
| 2017-12-26 | Peregrine Pharmaceuticals (USA - CA) | presdient - chief executive officer | nomination | Cancer - Oncology | Nomination | |
| 2017-12-22 | Roche (Switzerland) Accenture (Ireland) | digital data integration services | services contract | Technology - Services - Cancer - Oncology | Services contract | |
| 2017-12-22 | Formycon (Germany) Aristo Pharma (Germany) FYB202 GmbH & Co (Germany) | FYB202 - biosimilar version of ustekinumab - biosimilar ustekinumab | joint-venture | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Dermatological diseases - Digestive diseases | Joint-venture agreement | |
| 2017-12-22 | Antisense Therapeutics (Australia) myTomorrows (The Netherlands) | ATL1103 - atesidorsen | acromegaly | collaboration | Rare diseases - Hormonal diseases - Endocrine diseases | Collaboration agreement |
| 2017-12-21 | immatics biotechnologies (Germany) Roche (Switzerland) | tumour-associated peptide (TUMAP)-based cancer vaccine (including IMA942) and other cancer immunotherapies | gastric cancer, prostate cancer, non-small cell lung cancer | R&D - research - development - commercialisation | Cancer - Oncology | Exercise of an option agreement |
| 2017-12-21 | Zealand Pharma (Denmark) Beta Bionics (USA - MA) | dual hormonal artificial, or bionic, pancreas system - dual-hormone bionic pancreas utilizing both dasiglucagon (liquid formulation glucagon analog) and insulin | diabetes | development - collaboration | Metabolic diseases | Development agreement |
| 2017-12-21 | Janssen Biotech, a J&J company (USA - NJ) Legend Biotech USA and Legend Biotech, subsidiaries of Genscript Biotech Corporation (China) | LCAR-B38M | multiple myeloma | licensing - development - production - commercialisation | Cancer - Oncology | Licensing agreement |
| 2017-12-21 | Theradiag (France) MSD France (France) | LISA TRACKER® kits for the monitoring of Remicade® | services contract | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Dermatological diseases - Digestive diseases | Services contract | |
| 2017-12-21 | Crispr Therapeutics (Switzerland - UK) | chairman of the board of directors | nomination | Rare diseases - Genetic diseases - Hematological diseases | Nomination | |
| 2017-12-21 | LFB (France) | chief executive officer | nomination | Rare diseases - Genetic diseases - Hematological diseases | Nomination | |
| 2017-12-20 | Bluebird bio (USA - MA) Merck KGaA (Germany) | viral vectors | manufacturing - production | Production agreement | ||
| 2017-12-20 | TiGenix (Belgium) | Autoimmune diseases - Inflammatory diseases - Digestive diseases | Restructuring | |||
| 2017-12-20 | BMS (USA - NY) Taris Biomedical (USA - MA) | Opdivo® (nivolumab) and TAR-200 (GemRIS™) | muscle invasive bladder cancer (MIBC) | clinical research | Cancer - Oncology | Clinical research agreement |
| 2017-12-19 | Theradiag (France) HOB Biotech Group (China) | LISA TRACKER® monitoring assays, auto-immunity IVD tests | co-development - distribution | Diagnostic - Autoimmune diseases - Immunological diseases | Distribution agreement | |
| 2017-12-19 | Confo Therapeutics (Belgium) Roche (Switzerland) | small molecule agonists of an undisclosed G-protein coupled receptor (GPCR) | research - licensing - commercialisation | Neurological diseases - Developmental diseases | Research agreement | |
| 2017-12-19 | Boehringer Ingelheim (Germany) Roche (Switzerland) | Locked Nucleic Acid (LNA) oligonucleotides | inflammatory bowel diseases | research - R&D - development | Autoimmune diseases - Inflammatory diseases - Digestive diseases | Research agreement |
| 2017-12-19 | Celltrion Healthcare (South Korea) Hikma Pharmaceuticals (UK) | Truxima® (CT-P10 - biosimilar rituximab - biosimilar version of Mabthera®/Rituxan® ) | non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis | licensing | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Cancer - Oncology | Licensing agreement |
| 2017-12-19 | Five Prime Therapeutics (USA - CA) Zai Lab (China) | FPA144 | tumors that overexpress FGFR2b, including gastric and gastro-esophageal junction cancer. | licensing | Cancer - Oncology | Licensing agreement |
